Feature / Technical update

01 September 2014

Login to access this content

Technical update: Support available for new charity accounting framework

 

After a long period of relativelstability, the statement of recommended practice for the charities’ sector (SORP 2005) is being replaced, writes Nigel Davies. The change to the SORP, which sets out how accounting standards should be applied for the sector, is the result of a new GAAP (generally accepted accounting practice) applying for accounting periods beginning on or after 1 January 2015.

The updated GAAP has three new financial reporting standards (FRS100, FRS101 and principally FRS102) and the continuing, but amended, FRSSE (Financial reporting standard for smaller entities).

There are choices for charities based on their size and this is reflected in the two SORPs that have been developed in preparation for the new GAAP. The charities SORP (FRSSE) provides application guidance for the FRSSE.The charities SORP (FRS 102) provides application guidance for the new FRS 102.

Any charity of any size can follow the FRS 102 SORP. However, only those charities that fulfill two of three eligibility criteria below may follow the FRSSE SORP:?

  • Annual gross income of less than £6.5m
  • Total assets of less than £3.26m
  • Fewer than 50 employees.

Helpsheet 3, available from the dedicated SORP micro-site (see box), considers differences between the FRSSE and FRS 102 SORPs.

In terms of the trustees’ annual report, two changes affect all charities. First, a charity must disclose its reserves policy or it must state it?does not have a reserves policy and give reasons. Second, all trustees who served in the accounting period and/or are in position at the time the report is signed must be named (this will only affect trustee bodies).

There is also a change that affects all larger charities – those required to have an audit. These must provide a description of the principal?risks and uncertainties facing the charity and?its subsidiary undertakings, as identified by the charity trustees, together with a summary of their plans and strategies for managing those risks. For more information on these and other changes refer to helpsheet 2.

Nigel Davies is the Charity Commission’s head of accountancy

Help online


The new SORPs and accompanying helpsheets were published on the dedicated charities SORP micro-site www.charitysorp.org. There are three helpsheets also available at www.charitysorp.org/ about-the-sorp/helpsheets:

  • Helpsheet 1 maps paragraphs in the 2005 SORP to the FRS 102 SORP?
  • Helpsheet 2 identifies the major differences between SORP 2005 and the FRS 102 SORP and includes an illustration showing how line headings for the SORP 2005 statement of financial activities (SOFA) map to FRS 102 SORP SOFA.
  • Helpsheet 3 identifies the differences between the FRSSE SORP and FRS 102 SORP.

 
FT finance data published

The release of more than a million lines of foundation trust financial data will allow foundations to compare their expenditure with that of peers, Monitor said.

The regulator said the data, which is free to download, would also allow armchair auditors to examine foundations’ finances. The information includes staff costs, income and private finance initiative payments.

The data is the raw material from foundation trusts’ annual reports for 2013/14, which has been published in aggregate form by Monitor.

Monitor financial reporting and risk director Jason Dorsett said the initiative made data on individual foundation accounts easier to find and use.

‘Monitor is committed to putting out data in a way that people can use to deliver new insights into the foundation trust sector that will benefit patients. We already make significant use of data, but we want foundation trusts and others to innovate in ways we might not have thought of.’

 
In brief

Monitor and NHS England are putting together 12 local payment examples showing how local areas can adopt payment approaches that support improvement in the quality and efficiency of care, including?through integration. The approaches cover person-centred care for the frail elderly and those with multiple long-term conditions; mental health services; and different risk sharing mechanisms.

Consultation on regulations for health service bodies’ auditor panels and their independence closes on 12 September. The consultation regulations are under the Local Audit and Accountability Act 2014, which abolishes the Audit Commission on 31 March 2015. NHS trusts and clinical commissioning groups will be responsible for appointing external auditors from the end of current audit contracts.

The Health and Social Care Information Centre has a new HRG4 grouper to support NHS England and Monitor’s 2015/16 tariff engagement process.

Monitor has published revised costing guidance, reflecting an updated materiality and quality score collection template.


Nice update: Green light for oral treatment for RRMS


Multiple sclerosis (MS) is a chronic, neurodegenerative disorder with multi-focal inflammatory demyelination affecting the brain, optic nerves and spinal cord, writes Stephen Brookfield. This leads to progressive neurological impairment and severe disability. (Demyelinating diseases damage nerves’ protective covering).

About 100,000 people in the UK have MS – some 2,500 are newly diagnosed each year. Relapsing-remitting MS (RRMS) is a clinical form of MS that affects about 80% of people at time of diagnosis. It is characterised by periods of remission followed by relapses (which may or may not result in disability).

There is no cure for MS. Pharmacological management of RRMS includes first-line use of disease-modifying agents to reduce the frequency and severity of relapses. Current treatment is through beta interferon therapies, glatiramer acetate or teriflunomide – the latter (NICE approved in January 2014) being the first tablet-form treatment for the disorder.

NICE has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a further oral option for adults with RRMS. It promotes anti-inflammatory activity and can inhibit expression of pro-inflammatory cytokines and adhesion molecules. It is anticipated some people may prefer an oral treatment to injectable alternatives. It is also believed there may be a reduced rate of relapses compared with beta interferons or glatiramer acetate.

The cost of a relapse is put at £1,900, based on current tariff price for the medical are of patients with MS without comorbidities or complications (HRG AA30B). Dimethyl fumarate also has a shorter washout period compared with other orally available treatments.

A single costing template has been developed to consider the cost impact of teriflunomide and dimethyl fumarate together.

Stephen Brookfield is senior costing analyst at NICE